Expression and Prognostic Value of Indoleamine 2,3-dioxygenase in Pancreatic Cancer

Tao Zhang, Xiang-Long Tan, Yong Xu, Zi-Zheng Wang, Chao-Hui Xiao, Rong Liu
Department of Hepatobiliary and Pancreatic Surgical Oncology, Chinese People’s Liberation Army General Hospital, Chinese People’s Liberation Army Medical School, Beijing 100853, China

Abstract

Background: Indoleamine 2,3-dioxygenase (IDO), an enzyme for tryptophan metabolism through the kynurenine pathway, exhibits an immunosuppressive effect and induces immune tolerance in tumor cells. The effects of IDO on pancreatic cancer are poorly understood. This study aimed to investigate the expression and prognostic significance of IDO in pancreatic cancer.

Methods: We evaluated the protein expression of IDO in PANC-1, CFPAC-1, and BxPC-3 cell lines with or without 48 h treatment by 500 U/ml interferon-γ (IFN-γ). We performed immunohistochemical staining and Western blot analysis for IDO expression in both pancreatic cancer and normal pancreas tissues obtained from Chinese PLA General Hospital from July 2012 to December 2013. Survival analysis was performed to correlate IDO expression and histopathologic parameters with overall survival. The Kaplan-Meier method and Cox proportional hazards regression model were conducted.

Results: PANC-1, CFPAC-1, and BxPC-3 cell lines expressed IDO at the protein level, and the relative expression amount increased after stimulation with 500 U/ml IFN-γ. Immunohistochemical analysis results revealed that high IDO expression was observed in 59% of pancreatic adenocarcinoma tissues. Compared with normal pancreatic tissues, pancreatic adenocarcinoma showed significantly higher IDO expression levels, especially among patients with high tumor node metastasis (TNM) stages ($\chi^2 = 4.550, P = 0.030$), poor histological differentiation ($\chi^2 = 5.690, P = 0.017$), and lymph node metastasis ($\chi^2 = 4.340, P = 0.037$). Kaplan-Meier survival curves showed that high IDO expression was correlated with low survival rates (hazard ratio [HR] = 0.49 $P = 0.009$). Multivariate analysis using Cox proportional hazards model indicated that lymph node metastasis (HR = 0.35 $P = 0.010$) and IDO expression (HR = 0.42 $P = 0.020$) were two independent prognostic predictors of pancreatic adenocarcinoma.

Conclusions: The study confirmed that high IDO expression in pancreatic adenocarcinoma was related to poor prognosis of patients. These findings provided evidence that IDO was involved in pancreatic adenocarcinoma progression and might serve as a relevant therapeutic target.

Key words: Immunohistochemistry; Indoleamine 2,3-dioxygenase; Pancreatic Neoplasms; Prognosis

INTRODUCTION

Pancreatic cancer is a highly common malignancy worldwide and is considered the 9th leading cause of cancer death in China. The disease is mainly characterized by rapid progression and metastasis. It is reported that about 80% of patients present with unresectable stages at diagnosis with distant metastases or locally advanced tumors. Surgery remains as the standard treatment for early-stage pancreatic cancer. With the development of medical techniques, novel treatment options can improve the prognosis of patients with unresectable pancreatic tumors. However, the 5-year survival rate for all patients with pancreatic cancer is less than 5%. Even patients who had undergone margin-negative (R0) surgical resection attained a 5-year survival rate of no more than 20%. Several studies elucidated that local immune suppression of the tumor microenvironment was the key for cancer growth, metastasis, and even tumor immune escape. Hence, elucidation of the involved molecules and the mechanisms in the generation, development, and metastasis of pancreatic cancer might...
contribute to disease prognosis and provide targets for therapeutic intervention.

Indoleamine 2,3-dioxygenase (IDO) is a rate-limiting enzyme that catabolizes tryptophan into a stable metabolite under the kynurenine pathway. Tryptophan is an essential amino acid for cell survival and cannot be synthesized in vivo.\cite{9} IDO activity considerably influences immune regulation. IDO exerts its immunosuppressive effect in several ways, such as by inducing immune tolerance to tumor antigens, suppressing T and natural killer cells by tryptophan deletion and generation, and activating regulatory T-cells (Tregs) which is characterized by immune suppression and dysfunction.\cite{10,11} Overexpression of IDO has been identified correlating with poor clinical outcome in some cancer types, including breast, gastric, nasopharyngeal, and liver cancers.\cite{12-15} However, the expression of IDO in pancreatic cancer and its prognostic value on pancreatic cancer has not been intensively studied.

To explore the effect of IDO in pancreatic cancer progression, we identified IDO in tumor tissues and analyzed the correlation of this molecule and clinicopathologic features of patients with overall survival.

**Methods**

**Cell lines and culture**

PANC-1, CFPAC-1, and BxPC-3 cells were obtained from China Infrastructure of Cell Line Resources. The cells were maintained in Dulbecco’s modified Eagle’s medium (HyClone Co., Logan, UT, USA) supplemented with 10% fetal bovine serum (HyClone Co., Logan, UT, USA) and 100 U/ml penicillin and streptomycin. The cells were grown at 37°C in a humidified 5% CO₂ air incubator and subcultured twice a week. For treatment, the cells were washed twice with phosphate-buffered saline (PBS) and 1 × 10⁶ cells were incubated in cell-culture plates with or without 500 U/ml interferon-γ (IFN-γ; Sigma Co., St. Louis, MO, USA) for 48 h.

**Patient selection and follow-up**

The study enrolled 80 patients with primary pancreatic adenocarcinoma from the Department of Hepatobiliary and Pancreatic Surgical Oncology, Chinese People’s Liberation Army General Hospital from July 2012 to December 2013. All the eighty pancreatic adenocarcinoma tissues were obtained from the patient at the time of surgery. The exclusion criteria were acute and severe postoperative complications and lack of clinical information. Histologic features were reviewed by two pathologists based on the current WHO criteria. Clinical data including age, gender, tumor size, tumor differentiation, tumor location, tumor node metastasis (TNM) stage, lymph node metastasis, and survival data were obtained from electronic medical records. All the patients were followed up until April 2016, with a median follow-up time of 40 months. Overall survival was defined as the time from the date of surgery to the date of death or last visit. This study was approved by the Ethics Committee of the People’s Liberation Army General Hospital and carried out in accordance with the approved guidelines. The principle of informed consents on the use of clinical specimens from each enrolled person was satisfied.

**Immunohistochemistry**

Eighty pancreatic adenocarcinoma tissue samples and five normal pancreas tissue samples were used for Immunohistochemistry staining. Initially, 5 μm tissue sections were mounted on silanized slides, dewaxed, and rehydrated. For antigen retrieval, the sections were placed in 0.01 mol/L sodium citrate buffer (pH 6.0), heated in a microwave oven at the maximum power for 15 min, and cooled for 30 min. The sections were then washed with 0.05 mol/L PBS. Non-specific endogenous peroxidase activity was blocked with 3% H₂O₂ in methanol for 30 min at room temperature. Non-specific binding was blocked by incubation in 10% normal goat serum with 0.05% Triton X-100 (Sigma Co., St. Louis, MO, USA) in PBS. The sections were incubated at 4°C overnight with IDO antiserum (Abcam Co., Cambridge, MA, USA) diluted at 1:200 in PBS with 5% bovine serum albumin (BSA; Amresco Inc., Solon, OH, USA). The sections were then washed three times with PBS and incubated with the goat anti-mouse secondary antibody (GAM, Abcam Co., Cambridge, MA, USA) 1:200 for 1.5 h at room temperature. The sections were washed with PBS, incubated with the streptavidin-peroxidase complex (SP-HRP, Abcam Co., Cambridge, MA, USA) 1:200 for 1.5 h, and washed again in PBS. IDO immunoreactivity was visualized with diaminobenzidine and H₂O₂ for 2 min, followed by hematoxylin counterstaining. Finally, the sections were dehydrated in ethanol and mounted. Tissue sections incubated with PBS buffer instead of the IDO antiserum was used as negative control. Tissue sections of normal lymph node which was considered a positive IDO expression tissue were used as positive controls.

**Evaluation of Immunohistochemistry staining**

IDO expression was assessed by semi-quantitative evaluation of staining intensity and the percentage of positive tumor cell in each tissue core. The proportion score represented the percentage of tumor cells by IDO staining (0: none; 1: <25%; 2: 25–50%; 3: >50%). The intensity score signified the staining intensity in positively stained cells (0: None; 1: Weak; 2: Moderate; and 3: Strong). The overall IDO expression score in each sample was determined by multiplying the proportion (0–3) and intensity score (0–3). Staining was analyzed in two or more cores to standardize the analysis. Six photomicrographs of independent areas were chosen for each core. In the present study, the IDO expression score >4 was defined as high IDO expression and ≤4 as low expression.

**Western blotting**

Pancreatic cancer cell lines, five tissue samples of early stage (Stages I/II) pancreatic adenocarcinoma, five tissue samples of advanced pancreatic adenocarcinoma.
(Stages III/IV), and five normal pancreas tissue samples were used for Western blot analysis. Proteins were extracted from cancer tissues using nondenaturing lysis buffer. Protein concentrations were determined using Bradford protein assay reagent (Sigma Co., St. Louis, MO, USA) with BSA as a standard. Protein lysate (150 μg) was then subjected to electrophoresis on 12.5% (w/v) sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to polyvinyldene difluoride membranes (Bio-Rad Laboratories, Hercules, CA, USA). The membranes were blocked with 5% (w/v) nonfat milk and 0.01% (v/v) Tween-20 (Sigma Co., St. Louis, MO, USA) in tris-buffered saline (TBS; pH 7.6) for 3 h at room temperature and incubated with IDO and glyceraldehyde-3-phosphate dehydrogenase antiserum (Abcam Co., Cambridge, MA, USA) diluted at 1:1000 in TBS overnight at 4°C. The membrane was washed for 30 min with three changes in TBS. Subsequently, a 1:5000 dilution of the goat anti-rabbit/mouse IgG alkaline phosphatase-linked secondary antibody (Sigma Co., St. Louis, MO, USA) was incubated at room temperature for 3 h. The membrane was then washed for 30 min with three changes in TBS and processed for development using an alkaline phosphatase substrate, namely, bromochloroindolyl phosphate/nitro blue tetrazolium (Sigma Co., St. Louis, MO, USA), at room temperature. The relative levels of intensity of each blot were densitometrically scanned and analyzed.

Statistical analysis
SPSS 17.0 statistical software (SPSS Inc., Chicago, IL, USA) was used. Data were expressed as mean ± standard error (SD). Student’s t-test was used to compare data between two groups, and one-way analysis of variance (ANOVA) was employed for data comparison among multiple groups. Pearson Chi-square test or Fisher’s exact test was used to comparing categorical variables. Survival analysis was performed in accordance with Kaplan-Meier method. Univariate and multivariate analyses were conducted to relate IDO expression and histopathologic parameters with survival of patients with pancreatic adenocarcinoma using the Cox proportional hazards regression model. Log-rank test was employed for comparison of survival among groups. A value of \( P < 0.05 \) was considered statistically significant.

RESULTS
Indoleamine 2,3-dioxygenase expression in PANC-1, CFPAC-1, and BxPC-3 cell lines
Western blotting results displayed that all the three pancreatic cancer cell lines expressed IDO at the protein level [Figure 1a]. IDO expression relatively increased after stimulation with 500 U/ml IFN-γ [Figure 1b].

Immunohistochemical expression of indoleamine 2,3-dioxygenase in pancreatic adenocarcinoma and normal pancreatic tissues
IDO expression was examined in eighty pancreatic adenocarcinoma tissue samples and five normal pancreas tissue samples by immunohistochemical staining. IDO protein expression was observed in pancreatic adenocarcinoma tissue samples at various levels in the cytoplasm of tumor cells [Figure 2]. IDO protein expression was not detected in normal pancreatic tissues. High IDO expression was found in 47 cases, with a prevalence rate of 59%. The 33 (41%) remaining cases displayed low or undetectable IDO expression.

Correlation of indoleamine 2,3-dioxygenase expression with clinicopathological factors in pancreatic adenocarcinoma tissues
The correlations of IDO expression with clinicopathological factors in pancreatic adenocarcinoma are shown in Table 1. The high expression of IDO was significantly correlated with histological differentiation (\( \chi^2 = 5.690, P = 0.017 \)), TNM stage (\( \chi^2 = 4.550, P = 0.030 \)), and lymph node metastasis (\( \chi^2 = 4.340, P = 0.037 \)), but not with the age (\( \chi^2 = 0.025, P = 0.870 \)), patient gender (\( \chi^2 = 0.018, P = 0.890 \)), tumor size (\( \chi^2 = 0.003, P = 0.950 \)), and location (\( \chi^2 = 3.030, P = 0.080 \)).

Indoleamine 2,3-dioxygenase expression in pancreatic adenocarcinoma tissues with different tumor node metastasis stages
Western blot analysis was performed to determine IDO protein expression in five tissue samples of early-stage (Stages I/II) pancreatic adenocarcinoma, five tissue samples of advanced (Stages III/IV) pancreatic

| Variables                  | n  | IDO expression, n | \( \chi^2 \) | \( P \) |
|---------------------------|----|-----------------|--------------|--------|
| Gender                    |    | High | Low |                  |        |
| Male                      | 49 | 29   | 20  | 0.018            | 0.890  |
| Female                    | 31 | 18   | 13  |                  |        |
| Age (years)               |    |      |     |                  |        |
| ≥60                       | 36 | 21   | 15  | 0.025            | 0.870  |
| <60                       | 44 | 26   | 18  |                  |        |
| Tumor size (cm)           |    |      |     |                  |        |
| ≥3.0                      | 27 | 11   | 6   | 0.003            | 0.950  |
| <3.0                      | 53 | 36   | 17  |                  |        |
| Tumor location            |    |      |     |                  |        |
| Head                      | 58 | 38   | 20  | 3.030            | 0.080  |
| Body and tail             | 22 | 9    | 13  |                  |        |
| Histological differentiation|   |      |     |                  |        |
| Well and moderately       | 37 | 16   | 21  | 5.690            | 0.017  |
| Poorly                    | 43 | 31   | 12  |                  |        |
| TNM stage                 |    |      |     |                  |        |
| I, II                     | 62 | 32   | 30  | 4.550            | 0.030  |
| III, IV                   | 18 | 15   | 3   |                  |        |
| Lymph node metastasis     |    |      |     |                  |        |
| Positive                  | 39 | 28   | 11  | 4.340            | 0.037  |
| Negative                  | 41 | 19   | 22  |                  |        |

IDO: Indoleamine 2,3-dioxygenase; TNM: Tumor node metastasis.
showed significantly increased overall survival rate ($P < 0.01$) compared to patients with high IDO expression. Moreover, univariate and multivariate analyses were conducted using the Cox proportional hazard model to analyze the correlation of IDO expression and other clinicopathological factors with patient prognosis. The results of univariate analysis indicated that TNM staging (hazard ratio [HR] = 4.82, $P = 0.001$), lymph node metastasis (HR = 0.38, $P = 0.003$), and IDO expression (HR = 0.49, $P = 0.009$) were related to the overall survival of patients with pancreatic adenocarcinoma [Table 2]. However, overall survival rate was not correlated with gender, age, tumor size, tumor location, and histological differentiation. Multivariate analysis revealed that lymph node metastasis (HR = 0.35, $P = 0.010$) and IDO expression (HR = 0.42, $P = 0.020$) were two independent prognostic predictors of pancreatic adenocarcinoma.

**Discussion**

Recently, a series of studies focused on the role of IDO in cancer prognosis, and their results indicated that this immunosuppressive enzyme was closely related to clinical outcomes.\[15-17\] On the basis of the clinical evidence for poor prognosis in tumors with high IDO expression, there has been increasing scientific interest in IDO as a molecular target for the development of immunotherapy drugs. IDO-inhibiting drugs might be used as an adjunctive treatment approach for cancers with IDO expression. Up to now, 1-methy-DL-tryptophan which is one of the IDO competitive inhibitors has been widely studied in vitro and in vivo, and underwent the phase I study for bioavailability and safety.\[18\] However, the prognosis value and therapeutic potential of IDO in pancreatic adenocarcinoma need further investigations.

In the present study, the in vitro results showed that PANC-1, CFPAC-1, and BxPC-3 cells expressed the IDO protein, and the expression level increased after stimulation with 500 U/ml IFN-$\gamma$ for 48 h. IFN-$\gamma$ is a cytokine which is critical for innate and adaptive immunity. Inflammatory reaction in the tumor microenvironment could enable T-cells to release IFN-$\gamma$. Moreover, this cytokine could
exhibit immunomodulatory effects through the regulation of IDO expression in tumor microenvironment. In this study, we analyzed the correlation of IDO expression with the clinicopathological factors of pancreatic adenocarcinoma.

Table 2: Univariate and multivariate analysis of overall survival in pancreatic adenocarcinoma ($n = 80$)

| Variables                  | Univariate analysis | Multivariate analysis |
|----------------------------|---------------------|-----------------------|
|                            | $HR$    | 95% CI     | $P$   | $HR$    | 95% CI     | $P$   |
| Gender                     | 0.74    | 0.44–1.23  | 0.250 | –       | –           | –     |
| Age                        | 1.39    | 0.84–2.29  | 0.200 | –       | –           | –     |
| Tumor size                 | 0.64    | 0.38–1.07  | 0.090 | –       | –           | –     |
| Tumor location             | 0.61    | 0.34–1.12  | 0.110 | –       | –           | –     |
| Histological differentiation| 0.77    | 0.47–1.29  | 0.320 | –       | –           | –     |
| TNM stage                  | 4.82    | 2.63–8.85  | 0.001 | 1.61    | 0.65–4.01  | 0.300 |
| Lymph node metastasis      | 0.38    | 0.23–0.64  | 0.003 | 0.35    | 0.17–0.74  | 0.010 |
| IDO                        | 0.49    | 0.29–0.84  | 0.009 | 0.42    | 0.20–0.88  | 0.020 |

$HR$: Hazard ratio; CI: Confidence interval; IDO: Indoleamine 2,3-dioxygenase; –: Not available; TNM: Tumor node metastasis.

Figure 3: IDO protein expression in early stage (Stages I/II, $n = 5$) pancreatic adenocarcinoma tissue, advanced pancreatic adenocarcinoma tissue (Stages III/IV, $n = 5$), and normal pancreas tissue ($n = 5$) shown by Western blotting. (a) Expression of IDO examined by Western blotting. (b) The relative protein level of IDO in pancreatic adenocarcinoma tissues with different TNM stages and normal pancreas tissues. *$P < 0.05$. IDO: Indoleamine 2,3-dioxygenase; TNM: Tumor node metastasis.

Figure 4: Kaplan-Meier survival curves according to IDO expression levels (a), lymph node metastasis (b), and TNM stage (c). IDO: Indoleamine 2,3-dioxygenase; TNM: Tumor node metastasis.
High IDO expression level was significantly correlated with histological differentiation, lymph node metastasis, and TNM staging. These three clinicopathological factors represent degrees of malignancy; thus, we speculated that IDO was linked with cancer progression in pancreatic adenocarcinoma. Other studies demonstrated that high levels of IDO were present in the advanced stages of ovarian carcinoma and colorectal cancer. Moreover, IDO expression was found in all invasive uterine cervical cancers, whereas noninvasive tumors presented a lower expression level. These findings suggest that IDO might enhance the proliferation, invasion, and metastatic abilities of cancer cells to represent a high degree of malignancy through various mechanisms. These tumor immune escape mechanisms include depletion of tryptophan from tumor microenvironments, toxic effects of kynurenine pathway metabolites, maintenance of inflammation in the tumor microenvironment, development of immune tolerance to tumor antigens, inhibition of T cells, generation and activation of Tregs, and promotion of tumor angiogenesis.

We further evaluated the effect of IDO expression and clinicopathological factors on patient prognosis. Patients with low IDO expression exhibited a significantly higher overall survival rate. Univariate analysis indicated that TNM stage, lymph node metastasis, and IDO were related to the overall survival rate of patient with pancreatic adenocarcinoma. Multivariate analysis revealed that lymph node metastasis and IDO expression were two independent prognostic predictors of pancreatic adenocarcinoma. This finding is consistent with recent reports on other tumors, such as colorectal cancer, ovarian cancer, hepatocellular carcinoma, and esophageal squamous cell cancer. Although TNM staging is also a prognostic predictor for cancer patients, this factor did not exhibit statistically significant correlation with overall patient survival as detected through multivariate analysis in the present study. This observation might be explained mainly by the notion that the statistical results were limited by the low number of cases and short observation period.

There are several limitations in this study. The number of enrolled patients was limited in this study. A large-scale multicenter study is needed to confirm these results. Another limitation was the noninclusion of the IDO action in pancreatic cancer progression. IDO could play an immunosuppressive role in tumor through multiple signaling pathways including mammalian target of rapamycin complex 1, general control nonderepressible 2 (GCN2), and aryl hydrocarbon receptor. The exact mechanism of IDO in the progression of pancreatic cancer will be analyzed in the future work.

In conclusion, the study confirmed that IDO expression in pancreatic adenocarcinoma is related to patient prognosis and might be used as an independent prognostic indicator. We hope that IDO could also be a therapeutic target for the treatment of pancreatic adenocarcinoma in the near future.

Financial support and sponsorship
Nil.

Conflicts of interest
There are no conflicts of interest.

References
1. Chen W. Cancer statistics: Updated cancer burden in China. Chin J Cancer Res 2015;27:1. doi: 10.3978/j.issn.1000-9604.2015.02.07.
2. Chiorean EG, Coveler AL. Pancreatic cancer: Optimizing treatment options, new, and emerging targeted therapies. Drug Des Devel Ther 2015;9:3529-45. doi: 10.2147/DDDT.S60328.
3. Lu Z, Dong TH, Si PR, Shen W, Bi YL, Min M, et al. Continuous low-dose-rate irradiation of iodine-125 seeds inhibiting perineural invasion in pancreatic cancer. Chin Med J 2016;129:2460-8. doi: 10.4103/0366-6999.191777.
4. Yan L, Chen YL, Su M, Liu T, Xu K, Liang F, et al. A single-institution experience with open irreversible electroporation for locally advanced pancreatic carcinoma. Chin Med J 2016;129:2920-5. doi: 10.4103/0366-6999.195476.
5. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016;66:7-30. doi: 10.3322/caac.21332.
6. Harden JL, Egilmez NK. Indoleamine 2,3-dioxygenase and dendritic cell tolerogenicity. Immunol Invest 2012;41:738-64. doi: 10.3109/08820139.2012.676122.
7. Moon YW, Hajjar J, Hwu P, Naing A. Targeting the indoleamine 2,3-dioxygenase pathway in cancer. J Immunother Cancer 2015;3:51. doi: 10.1186/s40425-015-0094-9.
8. King NJ, Thomas SR. Molecules in focus: Indoleamine 2,3-dioxygenase. Int J Biochem Cell Biol 2007;39:2167-72. doi: 10.1016/j.biocel.2007.01.004.
9. Huang L, Baban B, Johnson BA 3rd, Mellor AL. Dendritic cells, indoleamine 2,3 dioxygenase and acquired immune privilege. Int Rev Immunol 2010;29:133-55. doi: 10.3109/08820139.2010.534969.
10. Gu W, Zhang Q, Li CS. Effect of splenic regulatory T-cell apoptosis on the postresuscitation immune dysfunction in a porcine model. Chin Med J 2016;129:1577-83. doi: 10.4103/0366-6999.184481.
11. Bi WW, Zhang WH, Yin GH, Luo H, Wang SQ, Wang H, et al. Analysis of indoleamine 2-3 dioxygenase (IDO) and EGFR co-expression in breast cancer tissue by immunohistochemistry. Asian Pac J Cancer Prev 2014;15:5535-8. doi: 10.7314/APJCP.2014.15.14.5535.
12. Ben-Haj-Ayed A, Moussa A, Ghedira R, Gabbouj S, Miled S, Bouzid N, et al. Prognostic value of indoleamine 2,3-dioxygenase activity and expression in nasopharyngeal carcinoma. Immunol Lett 2016;169:23-32. doi: 10.1016/j.imlet.2015.11.012.
13. Liu H, Shen Z, Wang Z, Wang X, Zhang H, Qin J, et al. Increased expression of IDO associates with poor postoperative clinical outcome of patients with gastric adenocarcinoma. Sci Rep 2016;6:21319. doi: 10.1038/srep21319.
14. Pan K, Wang H, Chen MS, Zhang HK, Weng DS, Zhou J, et al. Expression and prognosis role of indoleamine 2,3-dioxygenase in hepatocellular carcinoma. J Cancer Res Clin Oncol 2016;134:1247-53. doi: 10.1007/s00432-016-0935-1.
15. Isla Larrain MT, Rabassa ME, Lucunza E, Barbera A, Creton A, Segal-Eiras A, et al. IDO is highly expressed in breast cancer and breast cancer-derived circulating microvesicles and associated to aggressive types of tumors by silico analysis. Tumour Biol 2014;35:6511-9. doi: 10.1007/s13277-014-1859-3.
16. Jacheqiemier J, Bertucci F, Finetti P, Externi B, Charafe-Jauffret E, Thibult ML, et al. High expression of indoleamine 2,3-dioxygenase in the tumour is associated with medullary features and favourable outcome in basal-like breast carcinoma. Int J Cancer 2012;130:96-104. doi: 10.1002/ijc.25979.
17. Yang C, Zhou Y, Zhang L, Jin C, Li M, Ye L. Expression and function analysis of indoleamine 2 and 3-dioxygenase in bladder urothelial carcinoma. Chin Med J 2015;9:1768-75.
18. Soliman HH, Minton SE, Han HS, Ismail-Khan R, Neuger A, Khambari F, et al. A phase I study of indoximod in patients with cancer.
19. Tanizaki Y, Kobayashi A, Toujima S, Shiro M, Mizoguchi M, Mabuchi Y, et al. Indoleamine 2,3-dioxygenase promotes peritoneal metastasis of ovarian cancer by inducing an immunosuppressive environment. Cancer Sci 2014;105:966-73. doi: 10.1111/cas.12445.

20. Cavia-Saiz M, Muñiz Rodríguez P, Llorente Ayala B, García-González M, Coma-Del Corral MJ, García Girón C. The role of plasma IDO activity as a diagnostic marker of patients with colorectal cancer. Mol Biol Rep 2014;41:2275-9. doi: 10.1007/s11033-014-3080-2.

21. Inaba T, Iino K, Kajiyama H, Shibata K, Yamamoto E, Kondo S, et al. Indoleamine 2,3-dioxygenase expression predicts impaired survival of invasive cervical cancer patients treated with radical hysterectomy. Gynecol Oncol 2010;117:423-8. doi: 10.1016/j.ygyno.2010.02.028.

22. Nakamura T, Shima T, Saeki A, Hidaka T, Nakashima A, Takikawa O, et al. Expression of indoleamine 2,3-dioxygenase and the recruitment of Foxp3-expressing regulatory T cells in the development and progression of uterine cervical cancer. Cancer Sci 2007;98:874-81. doi: 10.1111/j.1349-7006.2007.00470.x.

23. Iversen TZ, Andersen MH, Svane IM. The targeting of indoleamine 2,3-dioxygenase -mediated immune escape in cancer. Basic Clin Pharmacol Toxicol 2015;116:19-24. doi: 10.1111/bcpt.12320.

24. Munn DH, Mellor AL. Indoleamine 2,3-dioxygenase and metabolic control of immune responses. Trends Immunol 2013;34:137-43. doi: 10.1016/j.it.2012.10.001.

25. Schmidt SV, Schultz JL. New insights into IDO biology in bacterial and viral infections. Front Immunol 2014;5:384. doi: 10.3389/fimmu.2014.00384.

26. Munn DH, Mellor AL. IDO in the tumor microenvironment: Inflammation, counter-regulation, and tolerance. Trends Immunol 2016;37:193-207. doi: 10.1016/j.it.2016.01.002.

27. Jia Y, Wang H, Wang Y, Wang T, Wang M, Ma M, et al. Low expression of Bin1, along with high expression of IDO in tumor tissue and draining lymph nodes, are predictors of poor prognosis for esophageal squamous cell cancer patients. Int J Cancer 2015;137:1095-106. doi: 10.1002/ijc.29481.

28. Yun TJ, Lee JS, Machmach K, Shim D, Choi J, Wi YJ, et al. Indoleamine 2,3-dioxygenase-expressing aortic plasmacytoid dendritic cells protect against atherosclerosis by induction of regulatory T cells. Cell Metab 2016;23:852-66. doi: 10.1016/j.cmet.2016.04.010.

29. Wirthgen E, Hoeflich A. Endotoxin-induced tryptophan degradation along the kynurenine pathway: The role of indolamine 2,3-dioxygenase and aryl hydrocarbon receptor-mediated immunosuppressive effects in endotoxin tolerance and cancer and its implications for immunoparalysis. J Amino Acids 2015;2015:973548. doi: 10.1155/2015/973548.

30. Sonner JK, Deumelandt K, Ott M, Thome CM, Rauschenbach KJ, Schulz S, et al. The stress kinase GCN2 does not mediate suppression of antitumor T cell responses by tryptophan catabolism in experimental melanomas. Oncoimmunology. 2016;5:e1240858. doi: 10.1080/2162402X.2016.1240858.

31. Li Q, Harden JL, Anderson CD, Egilmez NK. Tolerogenic Phenotype of IFN-gamma-Induced IDO+ Dendritic Cells Is Maintained via an Autocrine IDO-Kynurenine/AhR-IDO Loop. J Immunol. 2016;197:962-70.